Objective:To evaluate the incidence and associated factors of gallstone formation in a series of patients treated with long-acting somatostatin analogs(SSA)for neuroendocrine neoplasms.Methods:A prospec-tively-collected database of patients with a diagnosis of neuroendocrine neoplasms,treated with somatostatin analogs at our institution between 2010 and 2022 was retrospectively analyzed.Patients'demographics and dis-ease characteristics were analyzed to evaluate the incidence and the factors related to biliary stone formation.Results:Eighty-three patients were included,among them 60 with gallbladder in situ and no history of stone disease,26(43.3％)developed gallstones after a mean of 18.5months(range 3～94)treatment period.The inci-dence of gallstone is related to duration of receiving somatostatin analogs treatment(OR:1.03,95％CI:1.01～1.05,P＜0.05).Previous cholecystectomy was associated with a lower incidence of gallstone formation.Among 11 patients who underwent cholecystectomy before the start of SSA,1(9.1％)patient developed common bile duct stones during SSA therapy.Conclusion:We observed a high incidence of gallstone disease in patients treated with long-acting SSA-treated for neuroendocrine neoplasm,SSA treatment duration is probably related to the occurrence of gallstone formation.
维普
万方数据